A Pivotal Phase 3 Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia - Trial NCT06389292
Access comprehensive clinical trial information for NCT06389292 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ascentage Pharma Group Inc. and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 486 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ascentage Pharma Group Inc.
Timeline & Enrollment
Phase 3
May 01, 2024
Mar 26, 2029
Primary Outcome
Overall Survival๏ผOS๏ผ
Summary
An international multicenter, randomized, double-blind, placebo-controlled, phase III pivotal
 registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with
 azacitidine (AZA) versus placebo combined with azacitidine in newly diagnosed acute myeloid
 leukemia who are not eligible for standard induction chemotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06389292
Non-Device Trial